The ability of a SARM to increase muscle mass may prove beneficial in postmenopausal women with stress urinary incontinence (SUI) where pelvic floor muscle weakness leads to unintentional loss of urine.
GTx is evaluating enobosarm in postmenopausal women with SUI. In a Phase 2 proof-of-concept clinical trial, data from which were announced in September 2017, a daily dose of enobosarm 3 mg (GTx-024) substantially improved stress urinary incontinence (SUI) in women, as well as related quality of life measurements. The Company currently has an ongoing, placebo-controlled Phase 2 study in postmenopausal women with SUI. More information about our clinical trials may be found here.
More information on Stress Urinary Incontinence may be found here.